Based on these considerations, this study aimed to investigate a customized multigene panel for detecting mutations in thyroid cancer oncogenic drivers (BRAF, KRAS, NRAS, EGFR, and PI3KCA) and correlate the obtained results with clinical and pathological characteristics of the affected patients. Here, BRAF is linked to thyroid gland carcinoma.